Baseline vs. on-treatment heart failure with preserved ejection fraction (HFpEF) in a real world cardio-oncology clinic: observational analysis of cancer therapy-related cardiovascular toxicity incidence and cancer treatment implications - Poll - MDSpire

Baseline vs. on-treatment heart failure with preserved ejection fraction (HFpEF) in a real world cardio-oncology clinic: observational analysis of cancer therapy-related cardiovascular toxicity incidence and cancer treatment implications

  • By

  • Berlinde von Kemp

  • Xavier Galloo

  • Bram Roosens

  • Bart Neyns

  • Rik Schots

  • Mark De Ridder

  • Bernard Cosyns

  • June 9, 2026

  • 0 min

Share

Original Source(s)

Baseline vs. on-treatment heart failure with preserved ejection fraction (HFpEF) in a real world cardio-oncology clinic: observational analysis of cancer therapy-related cardiovascular toxicity incidence and cancer treatment implications

  • by Berlinde von Kemp, Xavier Galloo, Bram Roosens, Bart Neyns, Rik Schots, Mark De Ridder, Bernard Cosyns

  • June 9, 2026

Related Content

Artificial Intelligence Enhanced Electrocardiogram Analysis for Age and Sex Classification in Youth

Is creatine kinase a valid aid in early cardiac muscle damage detection during treatment for childhood acute lymphoblastic leukemia? A case report

Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART)

The goal of this clinical trial is to evaluate if adaptive stereotactic body radiation therapy (SBRT) is a safe and effective way to treat prostate cancer in adults. It will assess the safety profile of adaptive SBRT over time.

  • April 23, 2026

  • 4 min